Hydroxyapatite-based nano-drug delivery system for nicotinamide mononucleotide (NMN): significantly enhancing NMN bioavailability and replenishing in vivo nicotinamide adenine dinucleotide (NAD+) levels

Objectives: This study addresses the bioavailability challenges associated with oral nicotinamide mononucleotide (NMN) administration by introducing an innovative NMN formulation incorporated with hydroxyapatite (NMN-HAP). Methods: The NMN-HAP was developed using a wet chemical precipitation and physical adsorption method. To assess its superiority over conventional free NMN, we examined NMN, nicotinamide adenine dinucleotide (NAD(+)), and nicotinamide riboside (NR) levels in mouse plasma and tissues following oral administration of NMN-HAP. Key findings: NMN-HAP nanoparticles demonstrated a rod-shaped morphology, with an average size of similar to 50 nm, along with encapsulation efficiency and drug loading capacity exceeding 40%. In vitro, drug release results indicated that NMN-HAP exhibited significantly lower release compared with free NMN. In vivo studies showed that NMN-HAP extended circulation time, improved bioavailability compared with free NMN, and elevated plasma levels of NMN, NAD(+), and NR. Moreover, NMN-HAP administration displayed tissue-specific distribution with a substantial accumulation of NMN, NAD(+), and NR in the brain and liver. Conclusion: NMN-HAP represents an ideal formulation for enhancing NMN bioavailability, enabling tissue-specific delivery, and ultimately elevating in vivo NAD(+) levels. Considering HAP's biocompatible nature and versatile characteristics, we anticipate that this system has significant potential for various future applications. [GRAPHICS] .

Automated summary

This study introduces a formulation called NMN-HAP, which incorporates hydroxyapatite, to address the challenges of oral NMN administration. The results show that NMN-HAP improves the bioavailability of NMN and enables tissue-specific distribution, ultimately increasing NAD(+) levels in vivo.